AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2020 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.25. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.58 million.
AngioDynamics stock opened at $20.50 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.68 and a quick ratio of 1.70. The firm has a market cap of $757.80 million, a PE ratio of 27.70 and a beta of 0.69. AngioDynamics has a 1-year low of $18.11 and a 1-year high of $25.48. The stock has a fifty day simple moving average of $19.49.
A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded AngioDynamics from a sell rating to a hold rating and set a $20.00 target price for the company in a research note on Tuesday, June 4th. TheStreet lowered AngioDynamics from a b rating to a c+ rating in a research note on Thursday, April 18th. BidaskClub lowered AngioDynamics from a hold rating to a sell rating in a research note on Monday, June 24th. Finally, ValuEngine lowered AngioDynamics from a buy rating to a hold rating in a research note on Friday, April 19th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. AngioDynamics presently has an average rating of Hold and an average price target of $21.50.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Article: What is insider trading?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.